From the Department of Surgery, Children's Mercy Hospital, Kansas City, Missouri.
University of Missouri-Kansas City School of Medicine, Kansas City, Missouri.
Pediatr Infect Dis J. 2021 Jan;40(1):44-48. doi: 10.1097/INF.0000000000002872.
The duration of antibiotic treatment after resolution of empyema in children is variable. We evaluated the efficacy and safety of a protocol-driven antibiotic regimen aimed to decrease antibiotic duration following treatment with fibrinolysis.
Our institutional protocol consisted of 7 further days of antibiotics upon removal of the thoracostomy tube, with the patient being afebrile, off supplemental oxygen, and having negative cultures. A prospective observational study was then performed between September 2014 and March 2019. Empyema recurrence and antibiotic-related complications were recorded. Results were compared with previously published data from the preprotocol era.
A total of 37 patients were included. Mean total duration of antibiotics decreased from 26 ± 6.5 days in the preprotocol group to 22 ± 9.7 days in the postprotocol group (P = 0.004). This resulted in a significant decrease in hospital stay from the preprotocol cohort to the postprotocol cohort, respectively (9.3 ± 4.8 d versus 6.8 ± 3.1 d, P = 0.003). Sixty-two percentage of the patients were intended to treat according to the protocol, with a 50% adherence rate. Patients in which the protocol was followed had an average of 2.8 fewer days of antibiotics after discharge (P = 0.004), although overall duration was not statistically different. Significantly fewer antibiotic-related complications were noted after protocol initiation. There was no difference in empyema recurrence or readmissions.
Institution of a protocol-driven approach to antibiotic duration following resolution of pleural space disease may reduce antibiotic duration and complications without reducing efficacy.
儿童脓胸消退后抗生素治疗的持续时间存在差异。我们评估了一种基于方案的抗生素治疗方案的疗效和安全性,该方案旨在减少纤维蛋白溶解治疗后抗生素的使用时间。
我们的机构方案包括在拔除胸腔引流管后再使用抗生素 7 天,此时患者体温正常、不吸氧且培养结果为阴性。然后在 2014 年 9 月至 2019 年 3 月进行了一项前瞻性观察研究。记录脓胸复发和抗生素相关并发症的情况。结果与方案实施前的已发表数据进行了比较。
共纳入 37 例患者。与方案实施前相比,方案实施后抗生素的总使用时间从 26±6.5 天缩短至 22±9.7 天(P=0.004)。这导致住院时间分别从方案实施前组到方案实施后组显著缩短(9.3±4.8 天比 6.8±3.1 天,P=0.003)。根据方案,有 62%的患者预期接受治疗,而实际遵医嘱治疗的比例为 50%。遵循方案的患者在出院后平均减少了 2.8 天的抗生素治疗(P=0.004),尽管总体持续时间无统计学差异。方案实施后抗生素相关并发症明显减少。脓胸复发或再入院率无差异。
在解决胸膜腔疾病后,采用基于方案的抗生素持续时间治疗方法可能会减少抗生素的使用时间和并发症,而不会降低疗效。